

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-32. (Canceled)
33. (Currently Amended) An endoprosthesis comprising:
an elongated hollow structure, having an interior surface and an exterior surface, the structure being deliverable into a body lumen of a patient for dwelling therein, the structure being expandable from an initial state of decreased outer diameter during delivery to an expanded state of increased outer diameter of the structure during dwelling; and
a lining comprising a synthetic polymer interfaced with a medication for delivery to the patient, the lining being in contact ~~continuous and non-detachably connected~~ with the interior surface or and/or the exterior surface of the structure and expandable therewith, the lining being relatively more wrinkled when the structure is in the initial state than when the structure is in the expanded state.
34. (Currently Amended) The endoprosthesis of claim 33 wherein the lining is positioned in contact with both the interior and the exterior surface ~~both within and outside an aperture~~ of the structure.
35. (Previously Presented) The endoprosthesis of claim 33 wherein the lining is biodegradable.
36. (Currently Amended) The endoprosthesis of claim 33 wherein the lining comprises ~~several~~ at least two layers.
37. (Canceled)
38. (Currently Amended) The endoprosthesis of claim 36 wherein the lining contains ~~pores~~ a plurality of through holes.

39 - 45. (Cancelled)

46. (Currently Amended) The endoprosthesis of claim ~~33~~ 39 wherein the elongated hollow ~~expandable endoprosthesis structure~~ is woven from metal.

47. (Canceled)

48. (Cancelled)

49. (Currently Amended) The endoprosthesis of claim ~~36~~ 33 wherein the ~~lining comprises~~ at least two layers~~[[,]]~~ are each ~~layer being~~ interfaced with a different medication.

50. (Cancelled)

51. (Currently Amended) The endoprosthesis of claim 36 wherein the at least two layers comprise an inner layer in contact with the interior surface of the structure and an outer layer in contact with an exterior surface of the structure ~~one layer of the several layers is positioned within the hollow structure and another layer of the several layers is positioned outside of the hollow structure.~~

52. (Currently Amended) The endoprosthesis of claim ~~38~~ 50, wherein the through holes ~~pores~~ have a diameter no larger than 0.5 μm .

53. (Currently Amended) The endoprosthesis of claim 36 wherein the at least two layers ~~one of the several layers biodegrades~~ biodegrade at a different rates ~~rate than another one of the several layers.~~

54. (Cancelled)

55. (Cancelled)

56. (Currently Amended) The endoprosthesis of claim 33, wherein ~~An endoprosthesis comprising:~~
~~an elongated hollow structure having an interior surface and an exterior surface,~~
~~the structure being deliverable into a body lumen of a patient for dwelling therein, the~~
~~structure being expandable from an initial state of decreased outer diameter during~~
~~delivery to an expanded state of increased outer diameter during dwelling; and~~
~~a lining comprising a medication for delivery to the patient, the lining being~~
~~continuous and connected with the interior surface and/or exterior surface of the~~
~~structure and expandable therewith, the lining being relatively more wrinkled when the~~
~~structure is in the initial state than when the structure is in the expanded state, the lining~~
~~being~~ is adapted to prevent release of the medication when the structure is in the initial
state and allow release of the medication when the structure is in the expanded state.
57. (Currently Amended) The endoprosthesis of claim 33 ~~56~~, wherein the hollow structure
further comprises a lateral aperture.
58. (Cancelled)
59. (New) The endoprosthesis of claim 33, wherein the synthetic polymer is chosen from the
group consisting of: poly-D,L-lactide, poly-D,L-lactide co-trimethylene carbonate,
albumin cross-linked with glutaraldehyde, or polyacrylic.
60. (New) An endoprosthesis comprising:
an elongated hollow structure, having an interior surface and an exterior
surface, the structure being deliverable into a body lumen of a patient for dwelling
therein, the structure being expandable from an initial state of decreased outer
diameter during delivery to an expanded state of increased outer diameter of the
structure during dwelling;

a double walled sleeve, having an inner wall, an outer wall, and an internal space therebetween, wherein the sleeve covers at least a portion of the exterior surface of the elongated hollow structure and is expandable therewith; and

at least one flexible delivery tube to deliver a medication to the internal space.

61. (New) The endoprosthesis of claim 60, wherein the outer wall of the sleeve has a plurality of openings.
62. (New) The endoprosthesis of claim 60, wherein the inner wall of the sleeve has a plurality of openings.
63. (New) The endoprosthesis of claim 61, wherein the inner wall of the sleeve has a plurality of openings and the outer wall of the sleeve has more openings than the inner wall of the sleeve.
64. (New) The endoprosthesis of claim 61, wherein the inner wall of the sleeve has a plurality of openings and the outer wall of the sleeve has less openings than the inner wall of the sleeve.
65. (New) The endoprosthesis of claim 60, wherein the flexible delivery tube is detachable.
66. (New) The endoprosthesis of claim 60, further comprising a plurality of flexible delivery tubes.
67. (New) The endoprosthesis of claim 60, wherein the sleeve is relatively more wrinkled when the structure is in the initial state than when the structure is in the expanded state.
68. (New) The endoprosthesis of claim 60, wherein the sleeve plastically deforms without fissuring during expansion.

69. (New) The endoprosthesis of claim 60, wherein the sleeve is adapted to prevent release of a medication when the structure is in the initial state and allow release of a medication when the structure is in the expanded state.
70. (New) The endoprosthesis of claim 60, wherein the sleeve further comprises a plurality of through holes fluidly isolated from the internal space to allow for diffusion of metabolites through the inner wall and outer wall of sleeve.
71. (New) The endoprosthesis of claim 60, wherein the sleeve is biodegradable and the inner wall and the outer wall biodegrade at different rates.
72. (New) The endoprosthesis of claim 60, wherein the structure further comprises a lateral aperture.
73. (New) The endoprosthesis of claim 60, wherein the sleeve comprises a synthetic polymer chosen from the group consisting of: poly-D,L-lactide, poly-D,L-lactide co-trimethylene carbonate, albumin cross-linked with glutaraldehyde, or polyacrylic.